ATE437855T1 - (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit - Google Patents

(4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit

Info

Publication number
ATE437855T1
ATE437855T1 AT05740478T AT05740478T ATE437855T1 AT E437855 T1 ATE437855 T1 AT E437855T1 AT 05740478 T AT05740478 T AT 05740478T AT 05740478 T AT05740478 T AT 05740478T AT E437855 T1 ATE437855 T1 AT E437855T1
Authority
AT
Austria
Prior art keywords
indol
tetrahydro
alzheimer
disease
treatment
Prior art date
Application number
AT05740478T
Other languages
English (en)
Inventor
Michela Bettati
Ian Churcher
Victoria Alexandra Doughty
Timothy Harrison
Emmanuela Nizi
Adam Smith
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE437855T1 publication Critical patent/ATE437855T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT05740478T 2004-05-07 2005-05-06 (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit ATE437855T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0410238.0A GB0410238D0 (en) 2004-05-07 2004-05-07 Therapeutic agents
PCT/GB2005/001756 WO2005108362A1 (en) 2004-05-07 2005-05-06 (4, 5, 6, 7-tetrahydro-1-h-indol-7-yl) acetic acid derivatives for treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
ATE437855T1 true ATE437855T1 (de) 2009-08-15

Family

ID=32482866

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05740478T ATE437855T1 (de) 2004-05-07 2005-05-06 (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit

Country Status (10)

Country Link
US (1) US7728022B2 (de)
EP (1) EP1748982B1 (de)
JP (1) JP2007536360A (de)
CN (1) CN1950337A (de)
AT (1) ATE437855T1 (de)
AU (1) AU2005240830B2 (de)
CA (1) CA2565214A1 (de)
DE (1) DE602005015697D1 (de)
GB (1) GB0410238D0 (de)
WO (1) WO2005108362A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0522908D0 (en) * 2005-11-10 2005-12-21 Merck Sharp & Dohme Therapeutic agents
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
WO2008113835A1 (en) * 2007-03-21 2008-09-25 Novartis Ag Process for preparing (r or s)-5-{1-azido-3-[6-methoxy-5-(3-methoxy-propoxy)-pyridin-3-ylmethyl]-4-methyl-pentyl}-3-alkyl-dihydro-furan-2-one
JP2011507909A (ja) 2007-12-20 2011-03-10 エンビボ ファーマシューティカルズ インコーポレイテッド 四置換ベンゼン
EP2378879A4 (de) 2008-12-16 2012-06-06 Merck Sharp & Dohme Triazolderivate für die behandlung von morbus alzheimer
WO2015109109A1 (en) 2014-01-15 2015-07-23 Forum Pharmaceuticals Inc. Fused morpholinopyrimidines and methods of use thereof
US10392338B2 (en) 2015-01-29 2019-08-27 Yissum Research Development Company, of The Hebrew University of Jerusalem Ltd. Spirofuranone compounds, derivatives thereof and processes for their preparation
US9802927B2 (en) 2015-06-10 2017-10-31 Denali Therapeutics, Inc. Oxadiazine compounds and methods of use thereof
CN109970681A (zh) * 2019-04-19 2019-07-05 安徽海康药业有限责任公司 一种瑞格列奈的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5118427B2 (de) 1972-11-01 1976-06-09
WO1999025340A1 (en) * 1997-11-14 1999-05-27 Eli Lilly And Company Treatment for alzheimer's disease
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
CA2357450A1 (en) 2000-09-29 2002-03-29 Warner-Lambert Company Phenoxazine analogs useful as amyloid aggregation inhibitors and treatment of alzheimer's disease and disorders related to amyloidosis
US7153882B2 (en) * 2000-11-02 2006-12-26 The United States Of America As Represented By The Department Of Health And Human Services Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof
EP1587798A4 (de) 2003-01-14 2007-06-27 Merck & Co Inc Geminal disubstituiertensaid-derivate als abeta-42-senkende mittel
US20080153817A1 (en) * 2003-08-07 2008-06-26 Dirk Beher Treatment for Alzheimer's Disease and Related Conditions

Also Published As

Publication number Publication date
CN1950337A (zh) 2007-04-18
DE602005015697D1 (de) 2009-09-10
WO2005108362A1 (en) 2005-11-17
GB0410238D0 (en) 2004-06-09
CA2565214A1 (en) 2005-11-17
US20070232678A1 (en) 2007-10-04
JP2007536360A (ja) 2007-12-13
US7728022B2 (en) 2010-06-01
AU2005240830A1 (en) 2005-11-17
EP1748982B1 (de) 2009-07-29
AU2005240830B2 (en) 2011-03-24
EP1748982A1 (de) 2007-02-07

Similar Documents

Publication Publication Date Title
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
CY1108514T1 (el) Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων
ATE455763T1 (de) Piperidine und verwandte verbindungen zur behandlung von alzheimer-krankheit
NO20064726L (no) Imidazolforbindelser for behandling av neurodegenerative forstyrrelser
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
GB0318447D0 (en) Therapeutic agents
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
ATE383853T1 (de) Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit
TW200505418A (en) Phenacyl 2-hydroxy-3-diaminoalkanes
WO2009067493A3 (en) 1,3,5 tri-subtituted benzenes for treatment of alzheimer&#39;s disease and other disorders
ATE392471T1 (de) Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
ATE496534T1 (de) Difluorierte piperidine zur behandlung von morbus alzheimer und verwandten leiden
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
ATE524171T1 (de) Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion bei der behandlung der parkinson-krankheit
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE402150T1 (de) Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
DE60219680D1 (de) Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties